Biogen Idec said it would price its newly approved multiple sclerosis drug Tecfidera at $54,900 annually, lower than those of rivals including Novartis' Gilenya but higher than analysts had forecast. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," Biogen spokeswoman Kate Niazi-Sai said.

Full Story:

Related Summaries